key: cord-0970751-4dog2s3r
authors: Bouman, Karlijn; Groothuis, Jan T.; Doorduin, Jonne; van Alfen, Nens; Udink ten Cate, Floris E. A.; van den Heuvel, Frederik M. A.; Nijveldt, Robin; van Tilburg, Willem C. M.; Buckens, Stan C. F. M.; Dittrich, Anne T. M.; Draaisma, Jos M. T.; Janssen, Mirian C. H.; Kamsteeg, Erik-Jan; van Kleef, Esmee S. B.; Koene, Saskia; Smeitink, Jan A. M.; Küsters, Benno; van Tienen, Florence H. J.; Smeets, Hubert J. M.; van Engelen, Baziel G. M.; Erasmus, Corrie E.; Voermans, Nicol C.
title: Natural history, outcome measures and trial readiness in LAMA2-related muscular dystrophy and SELENON-related myopathy in children and adults: protocol of the LAST STRONG study
date: 2021-08-12
journal: BMC Neurol
DOI: 10.1186/s12883-021-02336-z
sha: 2b6928b9243b9267cb0f942ca5ac0768118087e2
doc_id: 970751
cord_uid: 4dog2s3r

BACKGROUND: SELENON (SEPN1)-related myopathy (SELENON-RM) is a rare congenital myopathy characterized by slowly progressive proximal muscle weakness, early onset spine rigidity and respiratory insufficiency. A muscular dystrophy caused by mutations in the LAMA2 gene (LAMA2-related muscular dystrophy, LAMA2-MD) has a similar clinical phenotype, with either a severe, early-onset due to complete Laminin subunit α2 deficiency (merosin-deficient congenital muscular dystrophy type 1A (MDC1A)), or a mild, childhood- or adult-onset due to partial Laminin subunit α2 deficiency. For both muscle diseases, no curative treatment options exist, yet promising preclinical studies are ongoing. Currently, there is a paucity on natural history data and appropriate clinical and functional outcome measures are needed to reach trial readiness. METHODS: LAST STRONG is a natural history study in Dutch-speaking patients of all ages diagnosed with SELENON-RM or LAMA2-MD, starting August 2020. Patients have four visits at our hospital over a period of 1.5 year. At all visits, they undergo standardized neurological examination, hand-held dynamometry (age ≥ 5 years), functional measurements, questionnaires (patient report and/or parent proxy; age ≥ 2 years), muscle ultrasound including diaphragm, pulmonary function tests (spirometry, maximal inspiratory and expiratory pressure, sniff nasal inspiratory pressure; age ≥ 5 years), and accelerometry for 8 days (age ≥ 2 years); at visit one and three, they undergo cardiac evaluation (electrocardiogram, echocardiography; age ≥ 2 years), spine X-ray (age ≥ 2 years), dual-energy X-ray absorptiometry (DEXA-)scan (age ≥ 2 years) and full body magnetic resonance imaging (MRI) (age ≥ 10 years). All examinations are adapted to the patient’s age and functional abilities. Correlation between key parameters within and between subsequent visits will be assessed. DISCUSSION: Our study will describe the natural history of patients diagnosed with SELENON-RM or LAMA2-MD, enabling us to select relevant clinical and functional outcome measures for reaching clinical trial-readiness. Moreover, our detailed description (deep phenotyping) of the clinical features will optimize clinical management and will establish a well-characterized baseline cohort for prospective follow-up. CONCLUSION: Our natural history study is an essential step for reaching trial readiness in SELENON-RM and LAMA2-MD. TRIAL REGISTRATION: This study has been approved by medical ethical reviewing committee Region Arnhem-Nijmegen (NL64269.091.17, 2017–3911) and is registered at ClinicalTrial.gov (NCT04478981).

Selenoprotein N-related congenital myopathy (SEPN1or SELENON-RM) is a rare congenital myopathy with an estimated prevalence of 0.5 in 1000,000 [1] . Core features include slowly progressive axial muscle weakness, early-onset rigidity of the spine, scoliosis and respiratory insufficiency. Delayed motor development is the most common presenting sign. Muscle biopsies show multiminicores as the most common lesion, often associated with mild dystrophic features [2] . Laminin α2-related muscular dystrophy (LAMA2-MD) has a similar clinical phenotype, with an estimated prevalence of 4 in 500,000 [3] . It has a heterogeneous disease spectrum ranging from a severe, early-onset congenital muscular dystrophy (complete Laminin subunit α2 deficiency, also called merosin-deficient congenital muscular dystrophy type 1A (MDC1A)) to a mild, childhood-or adult-onset limb-girdle type muscular dystrophy (partial Laminin subunit α2 deficiency). Additionally, patients may suffer from epileptic seizures and may show characteristic diffuse brain white matter lesions on magnetic resonance imaging (MRI) [4] . The clinical diagnosis of SELENON-RM and LAMA2-MD is confirmed by recessive pathogenic variants in the SELENON gene (OMIM-number 606210) or LAMA2 gene (OMIM-number 156225), respectively [5] [6] [7] [8] [9] . Currently, no curative treatment options exist for neither SELENON-RM nor LAMA2-MD. Optimal pulmonary, cardiac, nutrition and orthopedic management, in combination with supportive care from rehabilitation and allied health care, is essential for preventing or treating severe complications [10, 11] . Further, promising new therapies are currently being developed [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] .

Selenoprotein N is an endoplasmic reticulum (ER) calcium sensor that responds to diminished luminal calcium levels by refilling the ER calcium stores [22] . SELENON-RM has striking similarities at the cellular level with classical mitochondrial diseases. This has led to the hypothesis that sonlicromanol, a new clinical stage chemical entity with a dual activity as antioxidant and redox modulator developed for mitochondrial oxidative phosphorylation disturbances, is also beneficial for patients with SELENON-RM [12, 13] . Interestingly, the first results of experiments in an animal model (SELE-NON knock-out zebrafish) showed improved muscular function (unpublished data). Further, other antioxidants are also hypothesized to be beneficial in the treatment of patients with SELENON-RM [13] [14] [15] . In general, the recognition of the interplay between mitochondrial bioenergetics and endoplasmic reticulum paves the way to the identification of potential treatment options [16, 17] . Laminin subunit α2 is an extracellular matrix protein that links with dystrophin on the inner side of the muscle membrane. This linkage is of high importance for normal skeletal muscle function as it stabilizes the sarcolemma and protects the muscle fibers from contraction-induced damage [23, 24] . Further, a metabolic impairment, with reduced mitochondrial respiration and enhanced glycolysis, was observed in human Laminin subunit α2 deficient muscle cells [25] . For LAMA2-MD, preclinical studies on the use of linker proteins, on exogenous administration of Laminin-111, on upregulation of LAMA1, on genome editing technology and on the use of antioxidant molecules are being performed in animal models [18-21, 26, 27] . Moreover, different research groups are working on revealing the precise pathophysiology, which could eventually help to design new treatment strategies for SELENON-RM [14, [28] [29] [30] [31] or LAMA2-MD [32] [33] [34] .

In order to pave the way towards clinical trials, it is essential to identify and characterize the patients clinically and genetically, and to select clinical and functional outcome measures that correlate with muscle function and that are sensitive to change over time. These outcome measures can be used to determine the effectivity of possible treatment options in clinical trials. Three large clinical studies have recently been performed, one in SELENON-RM and two in LAMA2-MD. We discuss the main findings below.

In SELENON-RM patients, a retrospective clinical, histologic and genetic analysis of 132 pediatric and adult patients (age range at last examination 2 to 58 years) was performed by Villar-Quiles et al. [2] . The main prognostic determinants for disease severity included scoliosis and respiratory management, body mass abnormalities and the specific SELENON mutation found in the patient. The latter indicates a genotype-phenotype association between bi-allelic null mutations and more severe disease. This study reports the largest SELENON-RM series and the first one including pediatric, adolescent and adult patients followed-up for several decades. Limitations of this study are its retrospective design, and the absence of functional measurements and convenient muscle visualizing techniques (i.e. muscle ultrasound or MRI) performed in a standardized manner.

In LAMA2-MD patients, a 5-year prospective natural history study that included 24 patients (age range 4 to 22 years) was performed by Jain et al. [35, 36] . The MFM-32 was found to be sensitive to change in ambulatory and non-ambulatory patients with LAMA2-MD. In non-ambulatory patients, they found a yearly decline in knee flexion strength and passive range of motion (PROM) of left elbow extension. Limitations of this study included the small subset of examinations performed and the absence of convenient muscle visualizing techniques. Further, patients were selected based on a convenience sample, possibly leading to a selection bias. Moreover, the age range limits the availability on natural history data in the very young children (< 4 years) and in older adult patients (> 22 years). Recently, Zambon et al. published a retrospective longitudinal study on 46 patients with LAMA2-MD of whom 42 patients had a complete and 4 patients had a partial Laminin subunit α2 deficiency (age range at last examination 12 to 22 years) [37] . They found a linear decrease in passive range of motion of left elbow extension and a linear decline in percentage predicted forced vital capacity. The intrinsic limitations included the retrospective nature of data collection, the limited age range and the inconsistencies in the use of functional scales throughout follow-up (i.e. frequency of examinations, indication for ancillary examinations etcetera).

In short, a prospective natural history study in an unselected group of patients including a plethora of clinical and functional outcome measures is lacking in both SELENON-RM and LAMA2-MD. Due to the promising ongoing preclinical studies, there is a high need to obtain natural history data in order to reach trial readiness for both muscle diseases. The similarities in the clinical phenotype of both muscle diseases allows us to combine both studies in one study protocol.

The primary objectives of this study in order to reach trials readiness, are:

1. to assess 1.5-year natural history in patients with SELENON-RM or LAMA2-MD; 2. to select relevant and sensitive clinical and functional outcome measures.

The secondary objectives of this study are:

3. to provide prevalence estimations of SELENON-RM and LAMA2-MD in the Netherlands and Flanders (Dutch-speaking part of Belgium); 4. to establish a well-characterized baseline cohort of patients with SELENON-RM or LAMA2-MD for prospective follow-up and recruitment for future clinical trials; 5. to assess the clinical features to optimize clinical management for patients with SELENON-RM or LAMA2-MD.

Our study on LAMA2-MD and SELENON-RM To Study Trial Readiness, Outcome measures and Natural history (LAST STRONG) is a prospective, single-center, observational study with repeated measurements performed at the Department of Neurology and Pediatric Neurology within the neuromuscular center of the Radboud university medical center, The Netherlands. Our center is a tertiary referral center for neuromuscular diseases. Participation in the study will not affect the usual care provided by the patient's own medical team. Patients are invited to visit our hospital four times over a period of 1.5 year, with an interval of six months. During these visits, a predefined subset of investigations will be performed (See Table 1 ). Further, medical records from routine clinical care will be requested. Our study has been approved by the medical ethical reviewing committee Region Arnhem -Nijmegen (NL64269.091.17; 2017-3911) and is registered at ClinicalTrials.gov (NCT04478981).

Based on the prevalence reported in previous studies on SELENON-RM and LAMA2-MD, we expect to identify between 20-30 patients in each disease group. Based on our experience in rare diseases, we estimate that around 50% of the patients will participate in the study. We therefore aim to include 10-15 participants in each disease group. Inclusion criteria include a genetic confirmation of SELENON-RM or LAMA2-MD by two recessive pathologic mutations in the SELENON or LAMA2 gene, respectively, or typical clinical and histological alterations combined with genetic confirmation in a first degree relative. Additionally, patients must be willing and able to complete (part of) the measurement protocol in the Radboud university medical center. If patients do not wish or are not able to visit our center, they are offered to participate in this study by sharing medical records, completing questionnaires, and undergoing a medical history and physical examination through home visits, video and/or telephone interview. Exclusion criteria are an insufficient understanding of the Dutch language and the unwillingness of the patient or his/her legal representatives to provide written informed consent for participation in our study.

Participants will be recruited non-selectively and consecutively in the periods from August 2020 to August 2021 (See Fig. 1 ). In order to estimate the prevalence and to provide data on the complete spectrum of patients with SELENON-RM or LAMA2-MD, we aim to reach all patients in The Netherlands and the Dutchspeaking part of Belgium (Flanders) in our study. All Dutch and Dutch-speaking Belgian (pediatric) neurologists, rehabilitation specialists and clinical geneticists are personally asked about potential participants. Additionally, all patients known at our own neuromuscular center will be personally informed. Moreover, we will directly recruit participants through promotion of our study on patient information days, social media and through patient organizations.

Date of birth, sex, weight (kg), height (m), comorbidity and medication will be recorded.

Upon inclusion in our study, all participants (or a first degree relative) have undergone genetic examination as part of regular diagnostic work-up. The genetics reports, including information on the specific genetic alterations, will be requested. Regarding LAMA2-MD, we expect to mostly include patients harboring the Dutch founder mutation in the LAMA2 gene (c.5562 + 5G > C). All genetic laboratories in The Netherlands will be contacted to inventory the number of patients diagnosed with SELENON-RM or LAMA2-MD in order to contrast this number against the number of participants in our natural history study.

Pathological records and stained slides will be requested from participants diagnosed with LAMA2-MD in whom muscle biopsy material was previously taken as part of regular diagnostic work-up. Hereby we aim to classify LAMA2-MD patients as either suffering from a complete or a partial Laminin subunit α2 deficiency.

All patients undergo a standard neurological examination by one assessor (KB a. The Brooke and Vignos scales provide ordinallevel data to assess the upper and lower extremity functions, respectively.

Neurological examination and functional measurements will be performed at all four visits.

Each visit, patients and/or their parent(s) will be asked to complete age-adapted questionnaires on quality of life, pain, fatigue, and activities and participation,. These questionnaires include: 

At all four visits, muscle thickness and muscle echogenicity (quantitative grayscale analysis and Heckmatt ultrasound score) of a subset of bilateral muscles (See Table 2 ) will be assessed by muscle ultrasound using an The predicted grayscale level is calculated using a reference equation including age, length, sex and weight [78, 79] . In addition, all ultrasound images will be visually evaluated using the semi-quantitative Heckmatt grading scale [80] . At visit 1 (t = 0) and visit 3 (t = 12 months), muscle features are additionally qualitatively and (semi-)quantitatively described through full body muscle MRI (1,5 Tesla, Siemens, Erlangen, Germany) in accordance with our locally developed scanning protocol including Dixon vibe and Short-TI Inversion Recovery (STIR) images [81] [82] [83] [84] . In accordance with previous studies on quantitative assessment of muscle MRI, the water and fat image of the Dixon sequence will be used to create a fat fraction map using MATLAB according to the following equation: Fat/(Fat + Water) [84] . The fat fraction map will be used to draw ROI (region of interest) per muscle using ImageJ software (ImageJ 1.47v, National Institutes of Health, USA). ROI will be drawn at predefined localization using the localizer sequences. All drawn ROI will be checked by a second clinician. Muscle crosssectional area and fat fractions will be calculated per ROI. The qualitative and semi-quantitative assessment will be performed by two independent assessors. It will include assessment of a predefined subset of bilateral muscles (See Table 3 ), including relative reduction of muscle volume (0: no reduction, 1: mild, reduction of < 30%, 2: moderate, reduction of 30-60%, 3: severe, reduction of > 60%, 4: non-identifiable muscle), fatty . A MRI will only be performed in patients of 10 years or older who are able to lie still for 45 min without respiratory equipment. At visit 1 (t = 0) and visit 3 (t = 12 months), an X-ray will be performed to assess deformities of the spine, including Cobb's angle (spinal curvature), pelvic obliquity, coronal and sagittal balance and lumbar flexion and extension [88, 89] . In order to assess bone density, a DEXA-scan of the right femoral neck and lumbar spine, including a vertebral fracture assessment, will be performed at visit 1 (t = 0) and visit 3 (t = 12 months) by using the Hologic Discovery A Horizon DXA System (S/ N 303053 M).

In order to describe the prevalence and progression of cardiac comorbidities and the need for routine cardiac assessment, patients (age ≥ 2 years) will undergo electrocardiogram and conventional transthoracic echocardiography (TTE) with speckle tracking and Tissue Doppler Imaging (TDI) at visit 1 (t = 0) and visit 3 (t = 12 months). All investigations will be performed by EACVI TTE certified sonographers using commercially available ultrasound systems (Affiniti70 General, Philips Healthcare, Best, the Netherlands for adult participants; or Vivid E9 or Vivid E95, GE Healthcare Ultrasound, Horten, Norway for pediatric participants). Offline analysis will be performed using dedicated software (AGFA Enterprise Imaging Cardiology version 8.1.2, AGFA Health-Care, Mortsel, Belgium). Global Longitudinal strain (GLS) will be measured using speckle tracking echocardiography on a three beats acquisition with a frame rate > 60 frames/sec. All measurements will be done according to the EACVI recommendations for cardiac chamber quantification [90] .

At all visits, patients (age ≥ 5 years) will undergo spirometry (forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), vital capacity (VC), peak cough flow (PCF)) in upright and supine position (SpiroUSB, Vyaire Medical connected to PC Spirometry software, Spida CareFusion 2.3.0.10 for Windows 7). Additionally, patients will undergo Maximum Expiratory Pressure (MEP), Maximum Inspiratory Pressure (MIP) and Sniff Nasal Inspiratory Pressure (SNIP) assessment in upright position (Micro RPM, Micro Medical, Care-Fusion, United Kingdom) [91] . Diaphragm ultrasound (MyLabTwice, Esaote SpA, Genoa, Italy) will be performed to assess diaphragm thickness (end expiratory and maximum inspiratory thickness) and thickening, and diaphragm echogenicity [92] [93] [94] .

After all visits, patients (age ≥ 2 years) are asked to wear an accelerometer (GENEActiv Original, Activinsights Ltd) for eight consecutive days. In the same time period, patients or their parents are asked to fill in a diary with their major activities, including sleeping hours, physical exercise, work and school. The GENEActiv is a tri-axial, wrist-worn accelerometer that will be set to measure at 87,5 Hz sampling [95] [96] [97] . The raw data will be converted into 1-s epochs by using the GENEActiv Software (v.3.3, 2019). We will use the gravity subtracted sum of vector magnitudes (SVMgs) as the activity measure. The SVMgs will be measured using the following equation: SVMgs = ∑√(x 2 + y 2 + z 2 ) -1 g. All data will be subsequently analyzed using MATLAB R2018a Update 4 (9.4.0.902940) for windows. A large subset of parameters will be addressed, including total activity (counts/day), the percentage of sedentary, light, moderate or vigorous activity, and total activity during sleep.

Due to the explorative character of our study, we will use descriptive statistics (mean, median, SD, 95%-CI) in order to summarize our data. Further, Spearman's correlation analysis and non-parametrical testing will be used to test the correlation between key parameters (i.e. age, ancillary investigations). Further, parameters will be corrected for genetic differences and partial or complete laminin subunit α2 deficiency. If reference values are available from literature, we will check for overlapping confidence intervals. In order to assess disease progression between subsequent measuring moments, we will perform the Wilcoxon signed-rank test (nonparametric continuous paired data) and the McNemar's test (categorial paired data). Multiple linear regressions will be used to explore the relationship between potential disease modifying variables and disease severity. Linear mixed models will be applied for analysis of differences in disease progression. Further, we will correct for multiple testing. We regard p < 0,05 as statistically significant. The Statistical Package for the Social Sciences (SPSS version 25, IBM, Armonk, New York) will be used to conduct all statistical analyses.

All data-management and data-monitoring will be performed within the Castor software (Version 2021) through direct entry or indirect entry via our electronic patient system (Epic, version May 2020).

The results of our natural history study on both SELENON-RM and LAMA2-MD will feed an international key-opinion-leader workshop in which the inand exclusion criteria, follow-up frequency and outcome measures for the international natural history studies will be discussed. When the results of preclinical and clinical work on promising new therapies continue to be encouraging, a clinical trial will be initiated.

Patients will be included between August 2020 and August 2021 and will be followed for 1,5 year. The last visit of the last included patient is expected to take place in the beginning of 2023.

Here we present the design of the LAST STRONG study, an extensive natural history study in an unselected cohort of Dutch-speaking SELENON-RM and LAMA2-MD patients (both children and adults) that includes a broad plethora of clinical and functional outcome measures. This enables us to assess the clinical spectrum of patients diagnosed with SELENON-RM or LAMA2-MD. Hereby, we aim to fulfill our primary objectives namely, 1. to assess 1.5-year natural history in patients with SELENON-RM or LAMA2-MD; and 2. to select relevant and sensitive clinical and functional outcome measures to reach trial readiness. In addition, our insights will be vital for reaching our secondary objectives, including making a prevalence estimation, establishing a wellcharacterized baseline cohort and providing adequate symptomatic management leading to improved clinical care. We propose elaborate qualitative and quantitative measurements adapted to the age and functional abilities of the participant. The structured approach enables us to give an explorative, full-spectrum clinical description of patients diagnosed with SELENON-RM or LAMA2-MD. Further, there is a well-organized health system with full access to (pediatric) neurology and rehabilitation for every patient. Our center also has a longstanding history of patient recruitment for scientific research. Altogether, this is expected to reduce selection bias. Further, as a tertiary referral center for neuromuscular diseases, we are widely experienced with the clinical care and the conduction of studies in patients with rare neuromuscular diseases. Finally, all participants can reach our study center within a three-hour travel by car, which enables us to execute a population based, nationwide study. A consequence of our natural history study might be that the most severely affected patients may be less likely to participate in our study. We expect to overcome this problem to some extent by requesting all available medical records, sending out questionnaires and performing a medical history by video call/telephone or home visits for all patients that are not able or do not wish to visit our center, provided that written informed consent is given. Due to nationwide travel restrictions and local hospital measures related to the COVID-19 pandemic, Belgian patients are limited in their participation in our study.

The rarity of SELENON-RM and LAMA2-MD will result in a relatively small sample size of Dutch-speaking patients, which limits our possibilities to verify correlations or differences in subgroups. Consequently, we aim to contribute to international collaborations in order to enlarge the availability of natural history data.

The importance to reach trial readiness is warranted by the recent development of promising new treatment strategies for SELENON-RM and LAMA2-MD. Outcome measures need to be reliable and specified per age and disease severity for an adequate measurement of disease progression. If these outcome measures are not reliable, possible positive effects of future treatments in clinical trials will remain to be unrevealed. Reliable outcome measures are thus required in order to start clinical trials.

Further, deep phenotyping of our cohort provides us with valuable information on disease characteristics, enabling us to fulfil one of our secondary objectives, i.e. improving clinical care. For example, participants in whom clinically significant (co)morbidities are found during our study, are referred to the appropriate medical specialists. Moreover, we can take these (co)morbidities into account for routine clinical care of patients with SELENON-RM or LAMA2-MD that are not participating in our natural history study.

In our study, we do not take into account the selection of serum or urine biomarkers in order to limit the burden for patients participating in this study. However, in a study by Bharucha-Goebel et al. serum samples of patients with LAMA2-MD were analyzed for biomarkers. Proteins that were found to be altered, primarily consisted of cytokines and proteins involved in development and cell adhesion. Of the proteins decreased, most were cytokines, growth factors, and protease inhibitors [98] . We recommend to take serum or urine biomarkers into account in future studies.

The LAST STRONG study is expected to provide natural history data, which can be used for the selection of relevant clinical and functional outcome measures in order to reach trial readiness in SELONON-RM and LAMA2-MD patients. Further, our study aims to optimize clinical management in patients diagnosed with SELENON-RM or LAMA2-MD.

Borg Rating Scale of Perceived Exertion; CHOP INTEND: The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders

DEXA-scan: Dual Energy X-ray absorptiometry; EK2: Egen Klassifikation version 2; FAC: Functional Ambulation Classification; FEV1: Forced expiratory volume in the first second; FVC: Forced vital capacity; HFMS: Hammersmith functional motor scale

Individualized Neuromuscular Quality of Life; IPA: Impact on Participation and Autonomy; LAMA2-MD: LAMA2-related muscular dystrophy

MDC1A: Merosin-deficient congenital muscular dystrophy type 1A

Maximum Expiratory Pressure; MFM-20/32: Motor function measure -20/32; miniBEST: Mini Balance Evaluation Systems Test; MIP: Maximum Inspiratory Pressure; MRC: Medical Research Council; MRI: Magnetic resonance imaging; PBS: Pediatric Balance Scale

PedsQL: Pediatric Quality of Life Inventory; PROM: Passive range of motion

Reasearch and Development-36; ROI: Region of interest; SELENON-RM: SELENON-related myopathy; SNIP: Sniff Nasal Inspiratory Pressure

SVMgs: The gravity subtracted sum of vector magnitudes; TDI: Tissue doppler imaging; TTE: Transthoracic echocardiography; VC: Vital capacity; 6MWT: 6-Minute Walk Test

The clinical, histologic, and genotypic spectrum of

Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-α2 chain-deficient congenital muscular dystrophy

Genotype-phenotype correlation in a large population of muscular dystrophy patients with LAMA2 mutations

LAMA2-related dystrophies: clinical phenotypes, disease biomarkers, and clinical trial readiness

Mutations in SEPN1 cause congenital muscular dystrophy with spinal rigidity and restrictive respiratory syndrome

Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: reassessing the nosology of early-onset myopathies

SEPN1: associated with congenital fiber-type disproportion and insulin resistance

Desmin-related myopathy with Mallory body-like inclusions is caused by mutations of the selenoprotein N gene

Consensus statement on standard of care for congenital muscular dystrophies

International Workshop Report Congenital muscular dystrophy 1A: the road to therapy

The KHENERGY study: safety and efficacy of KH176 in mitochondrial m. 3243A>G Spectrum disorders

Muscle redox disturbances and oxidative stress as pathomechanisms and therapeutic targets in early-onset myopathies

Oxidative stress in SEPN1-related myopathy: from pathophysiology to treatment

Selenoproteins and protection against oxidative stress: selenoprotein N as a novel player at the crossroads of redox signaling and calcium homeostasis

Defective endoplasmic reticulum-mitochondria contacts and bioenergetics in SEPN1-related myopathy

A maladaptive ER stress response triggers dysfunction in highly active muscles of mice with SELENON loss

A mutation-independent approach for muscular dystrophy via upregulation of a modifier gene

Linker proteins restore basement membrane and correct LAMA2-related muscular dystrophy in mice

Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy

Laminin and integrin in LAMA2-related congenital muscular dystrophy: from disease to therapeutics

Selenoprotein N is an endoplasmic reticulum calcium sensor that links luminal calcium levels to a redox activity

Distribution and function of laminins in the neuromuscular system of developing, adult, and mutant mice

Dystrophin protects the sarcolemma from stresses developed during muscle contraction

Bioenergetic impairment in congenital muscular dystrophy type 1A and Leigh syndrome muscle cells

CRISPR/Cas9-mediated exon inclusion in Lama2 gene alleviates dystrophic pathology in MDC1A mouse model in title abstract keyword

Calcium handling in a zebrafish model of SELENON congenital muscular dystrophy: World Muscle Society: Neuromuscular Disorders

Loss of selenoprotein N function causes disruption of muscle architecture in the zebrafish embryo

Aberrant regulation of epigenetic modifiers contributes to the pathogenesis in patients with selenoprotein N-related myopathies

an endoplasmic reticulum-localized selenoprotein linked to skeletal muscle pathology, counteracts hyperoxidation by means of redoxregulating SERCA2 pump activity

Laminin-deficient muscular dystrophy: Molecular pathogenesis and structural repair strategies

Exon skipping using antisense oligonucleotides for laminin-Alpha2-deficient muscular dystrophy

Cellular rescue in a zebrafish model of congenital muscular dystrophy type 1A

Results of a two-year pilot study of clinical outcome measures in collagen VI-and laminin alpha2-related congenital muscular dystrophies

Longitudinal changes in clinical outcome measures in COL6-related dystrophies and LAMA2-related dystrophies

LAMA2-related muscular dystrophy: natural history of a large pediatric cohort

Reference values of maximum isometric muscle force obtained in 270 children aged 4-16 years by hand-held dynamometry

Validity and reproducibility of hand-held dynamometry in children aged 4-11 years

Normative reference values for strength and flexibility of 1,000 children and adults

Hand-held myometry: reference values

Range of motion measurements: reference values and a database for comparison studies

The Children's Hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability

Validation of the Children's Hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND)

The Dubowitz neurological examination of the full-term newborn

Motor function measure: validation of a short form for young children with neuromuscular diseases

A motor function measure for neuromuscular diseases. Construction and validation study

The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation

Revised Hammersmith scale for spinal muscular atrophy: a SMA specific clinical outcome assessment tool

Pediatric balance scale: a modified version of the berg balance scale for the school-age child with mild to moderate motor impairment

Using psychometric techniques to improve the balance evaluation systems test: the mini-BESTest

Clinical trials in Duchenne dystrophy. Standardization and reliability of evaluation procedures

Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy

The six-minute walk test

Clinical gait assessment in the neurologically impaired. Reliability and meaningfulness

The correlation analysis of functional factors and age with duchenne muscular dystrophy

Clinical trial in Duchenne dystrophy. I. the design of the protocol

Measurement of the functional status of patients with different types of muscular dystrophy

Health related quality of life of Dutch children: psychometric properties of the PedsQL in the Netherlands

The PedsQL in pediatric patients with spinal muscular atrophy: feasibility, reliability, and validity of the pediatric quality of life inventory generic Core scales and neuromuscular module

Fatigue in children: reliability and validity of the Dutch PedsQL™ multidimensional fatigue scale

Translation, validation, and norming of the Dutch language version of the SF-36 health survey in community and chronic disease populations

The individualized neuromuscular quality of life questionnaire: cultural translation and psychometric validation for the Dutch population

The McGill pain questionnaire constructed for the Dutch language (MPQ-DV). Preliminary data concerning reliability and validity

Pain in children: comparison of assessment scales

The assessment of fatigue: psychometric qualities and norms for the checklist individual strength

Dimensional assessment of chronic fatigue syndrome

ACTIVLIM: a Rasch-built measure of activity limitations in children and adults with neuromuscular disorders

The development of a handicap assessment questionnaire: the impact on participation and autonomy (IPA)

Validity of the EK scale: a functional assessment of non-ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy

Psychophysical bases of perceived exertion

Neuromuscular ultrasound: a new tool in your toolbox

Neuromuscular ultrasound: clinical applications and diagnostic values

Skeletal muscle ultrasound

Muscle ultrasound from diagnostic tool to outcome measure--quantification is the challenge

Quantitative skeletal muscle ultrasound: diagnostic value in childhood neuromuscular disease

Muscle ultrasound: present state and future opportunities

Quantitative ultrasonography of skeletal muscles in children: normal values

Ultrasound imaging in the diagnosis of muscle disease

MRI in neuromuscular diseases: an emerging diagnostic tool and biomarker for prognosis and efficacy

MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study

Quantitative muscle MRI and ultrasound for facioscapulohumeral muscular dystrophy: complementary imaging biomarkers

Adding quantitative muscle MRI to the FSHD clinical trial toolbox

Muscle histology vs MRI in Duchenne muscular dystrophy

Muscle magnetic resonance imaging in patients with congenital muscular dystrophy and Ullrich phenotype

A short protocol for muscle MRI in children with muscular dystrophies

Reliability of radiographic parameters in neuromuscular scoliosis. Spine (Phila Pa 1976)

Scoliosis imaging: what radiologists should know

Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

ERS statement on respiratory muscle testing at rest and during exercise

Diaphragm sniff ultrasound: Normal values, relationship with sniff nasal pressure and accuracy for predicting respiratory involvement in patients with neuromuscular disorders

Diaphragmatic dysfunction in SEPN1-related myopathy

Respiratory muscle imaging by ultrasound and MRI in neuromuscular disorders

Validation of the GENEA accelerometer

Calibration of the GENEA accelerometer for assessment of physical activity intensity in children

Natural variability of daily physical activity measured by accelerometry in children with a mitochondrial disease

Serum biomarker discovery for congenital muscular dystrophies

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

We thank all patients and their relatives for participation in our study. Several authors of this publication are members of the Netherlands Neuromuscular Center (NL-NMD) and the European Reference Network for rare neuromuscular diseases (EURO-NMD).

Authors' contributions KB, JTG, JD, NA, FEAU, FMAH, RN, WCMT, SCFMB, ATMD, JMTD, MCHJ, EK, ESBK, SK, JAMS, BK, FHJT, HJMS, BGME, CEE and NCV contributed to the study conception and design. Further, KB, JTG, CEE, NCV drafted the manuscript or revised it critically. All authors have read and approved the final manuscript and agreed to be accountable for their contributions.

The study is financially supported by a competitively awarded, peer-reviewed grant from Stichting Spieren voor Spieren, Stichting Stofwisselkracht and Stichting Voor Sara, The Netherlands. The scientific advisory boards of the aforementioned foundations took into account the scientific quality of the study protocol, impact of the study, quality of the applicants and requested support. The funders have no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Stichting Spieren voor Spieren, Stichting Stofwisselkracht and Stichting Voor Sara.

The datasets generated during the current study will be available in the Donders Repository (https://data.donders.ru.nl).

This study is performed in accordance with the Declaration of Helsinki and has been approved by the medical ethical reviewing committee of Region Arnhem-Nijmegen (NL-number NL64269.091.17, dossier number 2017-3911; date of approval of last amendment: 8 July 2020). From all patients, or in case of children their parents or legal guardian, written informed consent will be obtained for participating in our study.

Not applicable.

Professor Jan A.M. Smeitink is Chief Executive Officer of Khondrion. All other authors declare that they have no competing interests.Author details 1 Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud university medical center, Nijmegen, The Netherlands.